Actively Recruiting
Albumin To Enhance Recovery After Acute Kidney Injury
Led by Ottawa Hospital Research Institute · Updated on 2025-05-01
856
Participants Needed
16
Research Sites
103 weeks
Total Duration
On this page
Sponsors
O
Ottawa Hospital Research Institute
Lead Sponsor
T
The Physicians' Services Incorporated Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Study objectives: To determine whether, in critically ill patients with Acute Kidney Injury requiring renal replacement therapy (AKI-RRT), randomization to receive intravenous hyperoncotic albumin 20-25% (100 mL X two doses) compared to control/placebo normal saline boluses (100 mL X two doses) given during RRT sessions, leads to: 1. An increase in organ support-free days (primary outcome) at 28 days following randomization; and 2. An increase in RRT-free days (principal secondary outcome) at 28 days following randomization.
CONDITIONS
Official Title
Albumin To Enhance Recovery After Acute Kidney Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Admitted to an intensive care or critical care unit for more than 24 hours
- Receiving vasoactive therapy and/or mechanical ventilation (including non-invasive ventilation)
- Immediate start of renal replacement therapy for acute kidney injury planned or additional RRT sessions planned after prior RRT in ICU
You will not qualify if you...
- Starting renal replacement therapy for reasons other than acute kidney injury (e.g., drug overdose, hypothermia)
- Known end-stage kidney disease before hospital admission
- Kidney transplant within the last 365 days
- Presence or suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy, or acute interstitial nephritis
- Advanced liver disease (Child Pugh class C), spontaneous bacterial peritonitis, or hepatorenal syndrome
- Use of acute peritoneal dialysis as first RRT method
- Contraindications to albumin, including traumatic brain injury, increased intracranial pressure, history of anaphylaxis to albumin, or refusal of albumin/blood transfusions
- Already had two or more RRT sessions during this ICU stay
- Medical limitations preventing RRT, mechanical ventilation, vasoactive medications, or plans for palliative care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
The Governors of the University of Calgary
Calgary, Alberta, Canada
Not Yet Recruiting
2
University of Manitoba - Health Sciences Centre
Winnipeg, Manitoba, Canada
Not Yet Recruiting
3
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Not Yet Recruiting
4
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada
Actively Recruiting
5
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
Actively Recruiting
6
Sunnybrook Health Sciences Centre
North York, Ontario, Canada, M4N 3M5
Actively Recruiting
7
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
8
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Actively Recruiting
9
Scarborough Health Network
Scarborough Village, Ontario, Canada
Not Yet Recruiting
10
Niagara Health System
St. Catharines, Ontario, Canada, L2S0A9
Actively Recruiting
11
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Not Yet Recruiting
12
Sinai Health System
Toronto, Ontario, Canada, M5G1X5
Actively Recruiting
13
Lakeridge Health
Whitby, Ontario, Canada, L1N 6K9
Not Yet Recruiting
14
Centre Integre de Sante et de Services Sociaux de Laval
Laval, Quebec, Canada, H7M3L9
Actively Recruiting
15
Centre Integre Universitaire de Sante et de Services Sociaux de L'Estrie - Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Actively Recruiting
16
University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Not Yet Recruiting
Research Team
E
Edward G Clark, MD MSc FRCPC
CONTACT
I
Irene Watpool, RN BScN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here